Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

341 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
Crespo M, Mira JA, Pineda JA, Van den Eynde E, Ríos-Villegas MJ, Collado A, Girón-González JA, López-Cortés LF, González-Serrano M, Rivero A, Merino D, Esteban JI. Crespo M, et al. Among authors: collado a. J Antimicrob Chemother. 2008 Oct;62(4):793-6. doi: 10.1093/jac/dkn262. Epub 2008 Jun 21. J Antimicrob Chemother. 2008. PMID: 18567911
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA, Mira JA, Gil Ide L, Valera-Bestard B, Rivero A, Merino D, Girón-González JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Carrillo-Gómez R, López-Cortés LF, Gómez-Mateos J. Pineda JA, et al. Among authors: collado a. J Antimicrob Chemother. 2007 Dec;60(6):1347-54. doi: 10.1093/jac/dkm373. Epub 2007 Oct 14. J Antimicrob Chemother. 2007. PMID: 17938129
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Mira JA, López-Cortés LF, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A, Ríos-Villegas MJ, González-Serrano M, Torres-Tortoso M, Macías J, Valera-Bestard B, Fernández-Fuertes E, Girón-González JA, Lozano F, Pineda JA; Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas. Mira JA, et al. Among authors: collado a. Antivir Ther. 2007;12(8):1225-35. Antivir Ther. 2007. PMID: 18240862
Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.
del Valle J, Mira JA, de los Santos I, López-Cortés LF, Merino D, Rivero A, Girón JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Pineda JA. del Valle J, et al. Among authors: collado a. AIDS. 2008 May 11;22(8):923-30. doi: 10.1097/QAD.0b013e3282ff8ad3. AIDS. 2008. PMID: 18453851
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Mira JA, López-Cortés LF, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, Martín-Rico P, Ríos-Villegas MJ, Hernández-Burruezo JJ, Merino D, López-Ruz MA, Rivero A, Muñoz L, González-Serrano M, Collado A, Macías J, Viciana P, Soriano V, Pineda JA. Mira JA, et al. Among authors: collado a. J Antimicrob Chemother. 2008 Dec;62(6):1365-73. doi: 10.1093/jac/dkn420. Epub 2008 Oct 13. J Antimicrob Chemother. 2008. PMID: 18854330 Clinical Trial.
Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
Mira JA, Gutiérrez-Valencia A, Gil Ide L, Merino D, Rivero A, Ríos-Villegas MJ, Delgado M, González-Serrano M, Collado A, Torres-Tortosa M, Omar M, López-Ruz MA, Macías J, Arponen S, Pineda JA. Mira JA, et al. Among authors: collado a. Clin Infect Dis. 2009 Oct 15;49(8):e84-91. doi: 10.1086/605677. Clin Infect Dis. 2009. PMID: 19772388
Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K, Mira JA, Ruiz-Morales J, Rivero A, Collado A, Torres-Cornejo A, Merino D, de Los Santos-Gil I, Macías J, González-Serrano M, Camacho A, Parra-García G, Pineda JA; SEGURIDAD HEPÁTICA Study Team of the Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Neukam K, et al. Among authors: collado a. J Antimicrob Chemother. 2011 Nov;66(11):2605-14. doi: 10.1093/jac/dkr357. Epub 2011 Sep 7. J Antimicrob Chemother. 2011. PMID: 21903660
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.
Mira JA, Neukam K, López-Cortés LF, Rivero-Juárez A, Téllez F, Girón-González JA, de los Santos-Gil I, Ojeda-Burgos G, Merino D, Ríos-Villegas MJ, Collado A, Torres-Cornejo A, Macías J, Rivero A, Pérez-Pérez M, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI); Red de Investigación en SIDA (RIS-HEP07). Mira JA, et al. Among authors: collado a. Eur J Clin Microbiol Infect Dis. 2015 Sep;34(9):1879-84. doi: 10.1007/s10096-015-2426-6. Epub 2015 Jun 27. Eur J Clin Microbiol Infect Dis. 2015. PMID: 26115631
Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.
Neukam K, Munteanu DI, Rivero-Juárez A, Lutz T, Fehr J, Mandorfer M, Bhagani S, López-Cortés LF, Haberl A, Stoeckle M, Márquez M, Scholten S, de Los Santos-Gil I, Mauss S, Rivero A, Collado A, Delgado M, Rockstroh JK, Pineda JA. Neukam K, et al. Among authors: collado a. PLoS One. 2015 Apr 29;10(4):e0125080. doi: 10.1371/journal.pone.0125080. eCollection 2015. PLoS One. 2015. PMID: 25923540 Free PMC article.
Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort.
Neukam K, Mira JA, Collado A, Rivero-Juárez A, Monje-Agudo P, Ruiz-Morales J, Ríos MJ, Merino D, Téllez F, Pérez-Camacho I, Gálvez-Contreras MC, Rivero A, Pineda JA; HEPAVIR SEG-HEP-2007 Study Group of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Neukam K, et al. Among authors: collado a. PLoS One. 2016 Feb 5;11(2):e0148104. doi: 10.1371/journal.pone.0148104. eCollection 2016. PLoS One. 2016. PMID: 26848975 Free PMC article. Clinical Trial.
341 results